Investors

Peder Holk Nielsen
Former CEO of Novozymes

Peder is a current senior advisor and investor. Peder was the President/CEO of Novozymes for 7 years from 2013 to 2020. In total he spent 35 years at Novozymes, 25 of which on the executive board. During this time he shaped the business strategy and culture into the global company it is today. 

Untitled design (91).png

Leopoldo Zambeletti
Former Head of Healthcare JP Morgan

Leopoldo is a current advisor and investor. Leopoldo led the European Healthcare Investment Banking team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years. Since 2013, Leopoldo has been an independent strategic advisor to life science companies on merger and acquisitions, out-licencing deals, and financing strategy. Leopoldo is a Non- Executive Director of Philogen, Nogra Pharma and the The Meatless Farm.

Hugh Grant
Last CEO of Monsanto 

Hugh is a current advisor and investor. Hugh was Chairman and CEO of Monsanto for 15 years until the $66 Billion sale to Bayer in 2018. During this time, Hugh successfully led the strategic transformation from a chemical company to a global seed and technology pioneer through strong R&D investment and over 70 strategic M&A transactions. He has been recognised globally as a leader in business and Life Sciences, renowned for his emphasis on innovation.

Lord David Prior
Chairman of NHS

David is a current advisor and investor. David is the current Chair of the English National Health Service. David was elected MP for North Norfolk in 1997. In 2015, David was appointed Parliamentary Under Secretary of State for Health and created a Life Peer.

Dr Jonathan Milner
Founder of Abcam

Jonathan is a current advisor and investor. Jonathan is the principal founder and former CEO of Abcam. After building Abcam from scratch to a multinational company with a market cap of £3 bn, Jonathan stepped down to focus on his activity as an angel investor and advisor. Jonathan brings a wealth of industry experience in bio-derived chemicals and unique entreprenerial experience from having built a deep tech company into a unicorn.

Claudio Castamagna
Former CEO of Goldman Sachs Europe

Claudio is a current advisor and investor. Claudio sits on the board of FTI Consulting. Previously, Claudio was the Chairman of AAA-Advanced Accelerator Applications when it was acquired by Novartis for $3.9 Bn in 2018. Mr. Costamagna worked in various positions within The Goldman Sachs Group, culminating as Chairman of the investment banking division for Europe, The Middle East and Africa (EMEA).

Dr David Hughes
Former Head of Anti-infectives Novartis 

David is an advisor and investor. David is currently Head of Clinical Development for Biopharmaceuticals at Sandoz AG, having previously held the role of Senior Global Program Head - Anti-infectives at Novartis and worked in managerial roles for Pfizer and McKinsey. David is a board-certified physician who holds an MD from University of Toronto and an MPH from Johns Hopkins University.

Funding Support

image (6).png

Ludwig Maximilian University of Munich

We are extremely grateful for our laboratory space at the LMU in Munich, which allowed us to get our research off the ground.

image (7).png
image (8).png

Exist- Grunderstipendium

Our first round of funding came in the form of a EXIST-Grunderstipendium, which enabled us to conduct a wealth of proof-of-concept experiments.

image (9).png

Innovate UK

We have been incredibly fortunate to benefit from four grants from Innovate UK, the UK's innovation agency. We're using these funds to accelerate the discovery of new antibiotics and fungicides.